Bathi sadurunge mbayar bunga, pajak, lan amortisasi: novartis.com (NVS)

The EBITDA metric demonstrates actual cash flow, where the value 22082.91 determines the parameter status. The supply stability of Novartis AG (NVS) is based on an extensive network of European plants. The Swiss brand authority guarantees physician trust, while the strategic focus on radionuclide therapy and new molecules creates powerful growth potential, offsetting the risks of expiring legacy patents.

Novartis AG (NVS) - Bathi operasional EBITDA saka 23.11.2025 nganti 11.11.2026

Novartis (NVS) - rincian metrik lan laporan keuangan

- nilai pasar lan prakiraan target analis:

Rega bursa Novartis Pharma|NVS - Bagan rega target

- indikator kapitalisasi bursa perusahaan:

Nilai pasar Novartis|NVS - Nilai Perusahaan

- rincian valuasi buku bisnis:

Ekuitas saben Saham Novartis|NVS - Kapitalisasi Buku|Kapitalisasi Pasar marang Nilai Buku novartis.com|NVS - Aset Agregat Perusahaan

- rincian struktur utang lan likuiditas bisnis:

- indikator bathi lan kelipatan valuasi:

NVS - Bathi resik|Proyeksi bathi mangsa ngarep Novartis AG|NVS - Rasio rega marang bathi|Pangali mangsa ngarep rega marang bathi novartis.com|NVS - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Novartis|NVS - Bathi operasional EBITDA|Bathi resik saben saham sajrone patang kuartal pungkasan Novartis|NVS - Bathi saben saham sajrone rolas wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan novartis.com|NVS - Wutah bathi resik saben saham ing taun iki|Dinamika bathi saben saham sing diarepake ing taun ngarep Novartis AG

Analisis kabeh metrik perusahaan:Novartis Pharma - NVS

Absolute operating profit measures the actual cash flow from core operations before taxes and interest expenses. The EBITDA trend visualizes the business's actual resilience to market shocks. This metric allows for an assessment of cash generation efficiency without the influence of capital structure. For Novartis AG (NVS), this indicator confirms the success of its transformation into an innovative developer. Profit growth here depends directly on the margins of key drugs and the protection of patents against generics.

Pesaing Novartis AG (NVS)